Lantheus falls as FDA extends review of experimental cancer diagnostic

Shares of drugmaker Lantheus Holdings LNTH.O fall 1.1% to $80.79

Co on Tuesday said the FDA extended its review of LNTH‑2501, an experimental radioactive diagnostic for cancer, by three months

Co's LNTH‑2501 is designed to help doctors spot neuroendocrine tumors, a type of cancer that starts in hormone‑producing cells, in adults and children - LNTH

FDA action pushes the decision date to June 29, 2026, co says

Co says the delay is linked to extra time needed to review manufacturing information, not the drug’s safety or effectiveness

LNTH‑2501 is not yet approved and is not available for sale in the U.S. - LNTH

Shares down ~26% in 2025